analysis of a randomized, controlled phase II study of VPA in patients with non-metastatic biochemical progression of (BCR) CaP, and the utility of combining DHA with VPA in potentially reducing side effects.
INTRODUCTION AND OBJECTIVES: Metastasis, the major driver of mortality in advanced prostate cancer, starts in the prostate when cancer cells start to invade the surrounding stromal tissue. This first step may involve EMT characterized by the loss of epithelial characteristics and the gain of mesenchymal features. Thus, developing therapeutic compounds specifically targeting this process may provide a therapeutic opportunity.
METHODS: In this study, we have developed a cell-based highthroughput screening protocol using the high content Operetta imaging platform to identify EMT cytotoxic compounds. A library of 2,640 compounds (Microsource) was screened on a co-culture of epithelial-like prostate cancer cells (PC3E GFP cells) and EMT-like prostate cancer cells (TEM 4-18 mCherry cells), both derived from the PC-3 cell line.
After 72h exposure to compounds, relative numbers of GFP-and mCherry-positive cells were quantitated using the Operetta system. Dose-response curves were established for each compound exhibiting a greater toxicity against EMT-like cells.
RESULTS: Among the compounds tested, monensin and salinomycin, both monovalent cation ionophores, exhibited a relatively greater toxicity against EMT-like cells. The highest potency and selectivity for the EMT-like cells was obtained with nigericin, another monovalent cation ionophore, followed by monensin and salinomycin. In addition to inducing apoptosis and a cell cycle arrest, monensin rapidly induced a swelling of golgi apparatus most likely resulting in a blockage of intracellular protein trafficking leading to cell death. In addition, we evaluated the toxicity of monensin in 24 cancer cell lines from different origins and classified them as resistant or sensitive. We analyzed publically available gene expression data and performed a Gene Set Enrichment Analysis to identify the gene sets differentially represented in the two groups. Supporting our hypothesis, the gene set involving EMT was enriched in the sensitive group.
CONCLUSIONS: In this study we identified monensin, salinomycin and nigericin as potent EMT-selective cytotoxic compounds. Understanding the mechanism-of-action of these compounds may lead to insight about the metastatic process and point to new therapeutic directions.
INTRODUCTION AND OBJECTIVES:
Recent studies have highlighted the existence of a highly lethal and drug-resistant variant of prostate cancer (PCa) termed neuroendocrine prostate cancer (NEPC). We have used a genomics-based drug-repositioning approach to identify piperlongumine, a natural product constituent of the fruit of the Long pepper (Piper longum), as a potential therapeutic against NEPC. The efficacy of this drug was tested in the NEPC cell line model NCI-H660 and compared to several other PCa cell lines in a modified WST-1 assay. Pre-clinical testing in mouse xenograft models of NEPC was also undertaken. Finally, the ability of piperlongumine to inhibit p-STAT3 signaling and promote apoptosis in cell lines and extracted tumors were measured by western blot analyses.
METHODS: PCa cell lines (LNCaP, 22Rv1, Du145, PC3, H660 and RWPE) were grown in complete media (RPM1 10%FBS, Advanced DMEM 5%FBS or Keratinocyte-SFM) and treated with piperlongumine for 3 or 7 days. IC50 values were generated from WST assay data using Prism6. Nude mice (n¼5) were injected with 1.5x106 H660 cells on each flank, and intraperitoneally administered with either 2.5mg/kg piperlongumine (n¼3) or DMSO (n¼2) daily for 3 weeks after tumors formed 200mm3 in volume. Tumor volume was measured daily with calipers. Western blot analyses were performed on protein lysates extracted from tumors and PCa cells treated with 0-10 mM of drug.
RESULTS: Piperlongumine was highly effective in inhibiting the growth of H660 cells (IC50 ¼ 0.4 mM) compared to LNCaP, 22Rv1, Du145, PC3, and RWPE cells. On average, the growth rate of untreated tumors was 2.7 times greater than those treated was piperlongumine. Treated H660 cells exhibited significant inhibition of p-STAT3 and increases in cPARP1 levels while other cell lines displayed little to no fluctuation.
CONCLUSIONS: Using drug-repositioning approaches we have identified a lead compound that inhibits the growth of the highly drug-resistant NEPC cell line NCI-H660. Remarkably, piperlongumine happens to be a water-soluble plant product with no known side effects. Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 THE JOURNAL OF UROLOGY â e677
Source RESULTS: Among the 613 PCa patients in the study, 11 (1.79%) carried CHEK2 germline pathogenic mutations, which was significantly higher than the estimate from the general population (ExAC database: 0.61%, P<0.0001). However, the mutation carrier rate in lethal PCa patients (5/261¼1.92%) was not significantly higher than either the localized cases in our study (6/352¼1.70%, P¼1.00) or in The Cancer Genome Atlas (2/406¼0.49%, P¼0.12). Among lethal cases, CHEK2 mutation carriers and non-carriers had similar mean age of death (77.0 and 73.0 years, respectively, P¼0.72) and mean time to death (10.0 and 8.0 years, respectively, P¼0.96). In the survival analysis of the entire study, CHEK2 mutations did not predict PCa-specific survival (Figure, . In contrast, germline mutations of BRCA1/2 and ATM predicted worse PCa specific survival (all log-rank P<0.05, comparing with CHEK2 carriers and non-carriers).
CONCLUSIONS: CHEK2 germline mutations increase risk for PCa, but do not differentiate risk of lethal from indolent disease or PCaspecific survival.
Source of Funding:
The study is partially supported by the National Key Basic Research Program Grant 973 of China (2012CB518301), the Key Project of the National Natural Science Foundation of China (81130047), PCW Fund, and the Rob Brooks Fund for Personalized Cancer Care at NorthShore University HealthSystem.
PD37-12 EVALUATION OF NICLOSAMIDE AS A POTENT INHIBITOR OF ANDROGEN RECEPTOR VARIANTS TO OVERCOME RESISTANCE TO ABIRATERONE AND ENZALUTAMIDE IN ADVANCED PROSTATE CANCER
Chengfei Liu*, Wei Lou, Joy Yang, Chong-Xian Pan, Primo Lara, Christopher Evans, Allen Gao, Sacramento, CA INTRODUCTION AND OBJECTIVES: Use of enzalutamide and abiraterone has improved treatment of advanced prostate cancer. However, development of resistance to these agents frequently occurs. Androgen receptor variants, particularly AR-V7, have been shown to drive resistance to abiraterone and enzalutamide. This study aimed to test whether niclosamide can overcome resistance and improve therapies by targeting androgen receptor variants.
METHODS: Resistant prostate cancer cells to enzalutamide and abiraterone were generated by continuous culturing the cells in media containing increasing doses of either enzalutamide or abiraterone. Drug screening was conducted using luciferase activity assay to determine the activity of AR-V7 after treatment with the compounds in the Prestwick Chemical Library, which contains about 1120 FDAapproved drugs. The effects of the identified inhibitors on AR-V7 activity and abiraterone/enzalutamide sensitivity were characterized in CRPC and enzalutamide/abiraterone resistant prostate cancer cells in vitro and in vivo.
RESULTS: Resistant prostate cancer cells to enzalutamide and abiraterone were generated, respectively. Both resistance cells express high levels of androgen receptor variants including AR-V7. Drug screening identified niclosamide, an anthelmintic agent approved by FDA for the treatment of tapeworm infections, as a potent AR-V7 inhibitor in prostate cancer cells. Niclosamide significantly decreased AR-V7 protein expression by protein degradation through a proteasome dependent pathway. Niclosamide also inhibited AR-V7 transcription activity and reduced the recruitment of AR-V7 to the PSA promoter. Niclosamide inhibited resistant prostate cancer cell growth in vitro and tumor growth in vivo. Furthermore, combination of niclosamide with either enzalutamide or abiraterone resulted in significantly inhibition of enzalutamide/abiraterone-resistant tumor growth. These results suggest that niclosamide enhances abiraterone/enzalutamide therapy and overcomes resistance to abiraterone/enzalutamide in castration resistant prostate cancer cells. Based on these preclinical studies, combination of niclosamide with abiraterone/enzalutamide trials are currently underway.
CONCLUSIONS: Niclosamide is a promising inhibitor of androgen receptor variants to treat advanced prostate cancer patients, especially those resistant to abiraterone or enzalutamide. Clinical trials with combination of niclosamide and abiraterone/enzalutamide are currently underway.
Source of Funding:
This work is supported in part by grants NIH/NCI CA140468, CA168601, CA179970, DOD PC130062, and US Department of Veterans Affairs, ORD VA Merits I01BX0002653, and by a Stand Up To CancerdProstate Cancer Foundation-Prostate Dream Team Translational Cancer Research Grant SU2C-AACR-PCF DT0812, made possible by the generous support of the Movember Foundation.
